Cargando…

Facts and prospects of peptide in targeted therapy and immune regulation against triple-negative breast cancer

Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer. Due to the lack of specific therapeutic targets, treatment options are limited, and the recurrence and metastasis rate is high, the overall survival of patients is poor. However, with the discovery of some new targ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Yongxiu, Zeng, Anqi, Song, Linjiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485606/ https://www.ncbi.nlm.nih.gov/pubmed/37691919 http://dx.doi.org/10.3389/fimmu.2023.1255820

Ejemplares similares

The role of peptides in reversing chemoresistance of breast cancer: current facts and future prospects
por: Huang, Yongxiu, et al.
Publicado: (2023)

Evaluation of triple negative breast cancer with heterogeneous immune infiltration
por: Quintana, Ángela, et al.
Publicado: (2023)

Prognostic value of various immune cells and Immunoscore in triple-negative breast cancer
por: Ren, Xinyu, et al.
Publicado: (2023)

Heterologous prime-boost cellular vaccination induces potent antitumor immunity against triple negative breast cancer
por: Niavarani, Seyedeh-Raheleh, et al.
Publicado: (2023)

Unveiling the veil of lactate in tumor-associated macrophages: a successful strategy for immunometabolic therapy
por: Tao, Hongxia, et al.
Publicado: (2023)

Sulindac sulfide as a non-immune suppressive γ-secretase modulator to target triple-negative breast cancer
por: Hossain, Fokhrul, et al.
Publicado: (2023)

Role of ICAM1 in tumor immunity and prognosis of triple-negative breast cancer
por: Zhou, Qin, et al.
Publicado: (2023)

Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer
por: Wei, Heng, et al.
Publicado: (2020)

A Deep Insight Into Regulatory T Cell Metabolism in Renal Disease: Facts and Perspectives
por: Han, Zhongyu, et al.
Publicado: (2022)

A Machine Learning Model to Predict the Triple Negative Breast Cancer Immune Subtype
por: Chen, Zihao, et al.
Publicado: (2021)

Prognostic value and immune landscapes of TERT promoter methylation in triple negative breast cancer
por: Lin, Fei, et al.
Publicado: (2023)

A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer
por: Del Bano, Joanie, et al.
Publicado: (2019)

Facts and Hopes in Immunotherapy for Early-Stage Triple-Negative Breast Cancer
por: Nederlof, Iris, et al.
Publicado: (2023)

Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer
por: Boissière-Michot, Florence, et al.
Publicado: (2022)

Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer
por: Huang, Pengfei, et al.
Publicado: (2023)

Targeting ANXA1 abrogates Treg-mediated immune suppression in triple-negative breast cancer
por: Bai, Fang, et al.
Publicado: (2020)

Immune landscape and risk prediction based on pyroptosis-related molecular subtypes in triple-negative breast cancer
por: Luo, Lixi, et al.
Publicado: (2022)

Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer
por: Zheng, Yiwen, et al.
Publicado: (2023)

Ferroptosis: the emerging player in remodeling triple-negative breast cancer
por: Li, Jie, et al.
Publicado: (2023)

CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth
por: Zhou, Ru, et al.
Publicado: (2019)

Immune checkpoints expression patterns in early-stage triple-negative breast cancer predict prognosis and remodel the tumor immune microenvironment
por: Zhang, Jinguo, et al.
Publicado: (2023)

Corrigendum: CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth
por: Zhou, Ru, et al.
Publicado: (2020)

Prognostic analysis of cuproptosis-related gene in triple-negative breast cancer
por: Sha, Shengnan, et al.
Publicado: (2022)

Tumor Mutation Burden and Immune Invasion Characteristics in Triple Negative Breast Cancer: Genome High-Throughput Data Analysis
por: Gao, Chundi, et al.
Publicado: (2021)

Facts and Perspectives: Implications of tumor glycolysis on immunotherapy response in triple negative breast cancer
por: Schreier, Ashley, et al.
Publicado: (2023)

The development of activatable lytic peptides for targeting triple negative breast cancer
por: Zhao, Hui, et al.
Publicado: (2017)

Peptide density targets and impedes triple negative breast cancer metastasis
por: Liu, Daxing, et al.
Publicado: (2018)

Histological Analysis of γδ T Lymphocytes Infiltrating Human Triple-Negative Breast Carcinomas
por: Hidalgo, Jose Villacorta, et al.
Publicado: (2014)

Identification of necroptosis-related subtypes and prognosis model in triple negative breast cancer
por: Pu, Shengyu, et al.
Publicado: (2022)

CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil
por: Nasiri, Fatemeh, et al.
Publicado: (2022)

Leveraging cryoablation and checkpoint inhibitors for high-risk triple negative breast cancer
por: Sardela de Miranda, Flávia, et al.
Publicado: (2023)

Characterization of Exosome-Related Gene Risk Model to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Triple-Negative Breast Cancer
por: Qiu, Pengjun, et al.
Publicado: (2021)

Spatiotemporal quantitative microRNA-155 imaging reports immune-mediated changes in a triple-negative breast cancer model
por: Skourti, Elena, et al.
Publicado: (2023)

3D Collagen Fiber Concentration Regulates Treg Cell Infiltration in Triple Negative Breast Cancer
por: Gao, Huan, et al.
Publicado: (2022)

Combination of verteporfin-photodynamic therapy with 5-aza-2’-deoxycytidine enhances the anti-tumour immune response in triple negative breast cancer
por: Banerjee, Shramana M., et al.
Publicado: (2023)

Enhanced Therapeutic Efficacy of Combining Losartan and Chemo-Immunotherapy for Triple Negative Breast Cancer
por: Zhao, Qing, et al.
Publicado: (2022)

Identification of HLA class I-restricted immunogenic neoantigens in triple negative breast cancer
por: Aparicio, Belén, et al.
Publicado: (2022)

Triple-Negative Breast Cancer: Intact Mismatch Repair and Partial Co-Expression of PD-L1 and LAG-3
por: Wu, Shafei, et al.
Publicado: (2021)

CD73 regulates zoledronate-induced lymphocyte infiltration in triple-negative breast cancer tumors and lung metastases
por: Petruk, Nataliia, et al.
Publicado: (2023)

Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells
por: Juliá, Estefanía Paula, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_lhhvkv8t6bhloammcit158qhhu